10-Q quarterly report · filed Nov 4, 2026

LivaNova PLC (LIVN) Q3 2026 10-Q Quarterly Report

Short answer

LivaNova PLC (LIVN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $393M (up 9.9% year over year) with net income of $34M.

Q3 2026 key financials · XBRL

Revenue
$393M
+9.9% YoY · +0.7% QoQ
Net income
$34M
+28.0% YoY · −68.4% QoQ
Operating margin
7.2%
Gross margin
67.4%
EPS (diluted)
$0.60
+20.0% YoY · −68.9% QoQ

Source: XBRL data from the LivaNova PLC (LIVN) Q3 2026 10-Q on SEC EDGAR. USD.

LivaNova PLC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $393.1M, up 9.9% YoY from $357.8M
  • Gross margin 67.4% vs 68.4% YoY; operating margin 7.2% vs 15.1%
  • Best segment Neuromodulation: revenue $166.1M, up 11.1%; income $62.1M, up 10.6%
  • Worst segment Cardiopulmonary: income $7.6M, down 69.3% despite revenue up 10.9% to $225.3M
  • Cash $563.5M vs $635.6M; nine-month operating cash flow $155.5M vs $171.9M, debt repayment $95.9M

Risk Factors

  • No material changes from the 2025 Form 10-K
  • Product liability and medical-device regulatory compliance risks remain significant
  • Competition and healthcare-market pressures continue affecting near-term performance
  • Liquidity, debt, and foreign-currency exposure remain carried-forward financial risks

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other LivaNova PLC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.